Curious about our science? Our CMO, Jay Barth, delivers a concise overview about our work to #RewriteRNA and the latest from our lead program in ABCA4 retinopathies all in one take!

Listen to what Jay has to say from the frontlines of #ARVO23 here 👇
https://www.ophthalmologytimes.com/view/arvo-live-ascidian-therapeutics-research-into-gene-therapy

Curious about our science? Our CMO, Jay Barth, delivers a concise overview about our work to #RewriteRNA and the latest from our lead program in ABCA4 retinopathies all in one take!

Listen to what Jay has to say from the frontlines of #ARVO23 here 👇
https://www.linkedin.com/posts/ascidian-therapeutics_arvo-live-ascidian-therapeutics-research-activity-7057034778151149568-tG5y?utm_source=share&utm_medium=member_desktop

We have an amazingly talented team and unique culture at Ascidian and we want to introduce you to the people behind our science.

That's why we're kicking off our first-ever social media series -- #MeetTeamAscidian! 👋

Each month, you'll get to meet a teammate to learn what they do at Ascidian, what they enjoy doing outside the office, and why they're motivated to #RewriteRNA for patients awaiting breakthroughs.

First up is Akiko Doi, PhD. Hear from her below 👇

https://www.linkedin.com/posts/ascidian-therapeutics_meetteamascidian-rewriterna-womenshistorymonth-activity-7046140496779309056-1ghG?utm_source=share&utm_medium=member_desktop

In support of #RareDiseaseDay, we’re sharing three things to know about #Stargardt disease and our work to #RewriteRNA for people affected by this genetically inherited eye disorder. Thanks to Tayla Cormier for sharing your passion and expertise! 👇

https://www.linkedin.com/posts/ascidian-therapeutics_rarediseaseday-stargardt-rewriterna-activity-7036333963602231296-d7j5?utm_source=share&utm_medium=member_desktop